FLGT * Stock Overview
Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Fulgent Genetics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$375.22 |
52 Week High | US$590.00 |
52 Week Low | US$345.01 |
Beta | 1.39 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -40.06% |
33 Year Change | -77.98% |
5 Year Change | n/a |
Change since IPO | -60.50% |
Recent News & Updates
Recent updates
Shareholder Returns
FLGT * | MX Healthcare | MX Market | |
---|---|---|---|
7D | 0% | 1.5% | -0.6% |
1Y | -40.1% | -24.7% | -3.5% |
Return vs Industry: FLGT * underperformed the MX Healthcare industry which returned -24.6% over the past year.
Return vs Market: FLGT * underperformed the MX Market which returned -2.6% over the past year.
Price Volatility
FLGT * volatility | |
---|---|
FLGT * Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 6.4% |
Market Average Movement | 4.4% |
10% most volatile stocks in MX Market | 6.7% |
10% least volatile stocks in MX Market | 2.5% |
Stable Share Price: FLGT * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FLGT *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,184 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
FLGT * fundamental statistics | |
---|---|
Market cap | Mex$10.92b |
Earnings (TTM) | -Mex$3.03b |
Revenue (TTM) | Mex$5.25b |
2.1x
P/S Ratio-3.6x
P/E RatioIs FLGT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FLGT * income statement (TTM) | |
---|---|
Revenue | US$287.53m |
Cost of Revenue | US$179.78m |
Gross Profit | US$107.75m |
Other Expenses | US$273.70m |
Earnings | -US$165.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -5.55 |
Gross Margin | 37.47% |
Net Profit Margin | -57.71% |
Debt/Equity Ratio | 0.3% |
How did FLGT * perform over the long term?
See historical performance and comparison